MIG
NBSE

Mariner Investment Group’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Mariner Investment Group’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-833
Closed -$57K – 66
2019
Q2 		$57K Sell
833
-387
-32% -$21.9K 0.1% 62
2019
Q1 		$55K Buy
+1,220
New +$58.3K 0.07% 76
2018
Q1 		– Sell
-75
Closed -$56K – 88
2017
Q4 		$56K Buy
+75
New +$29K 0.02% 88

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
HWA
Heritage Wealth Advisors Richmond, Virginia $2.91B AUM 24.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Mariner Investment Group's NBSE Position: Q3 2019 in Review

Mariner Investment Group sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q3 2019, closing a stake of 833 shares — an estimated $57K sold.

Mariner Investment Group first reported a position in NBSE in Q4 2017 and held it in 3 quarters. The position peaked at $57K in Q2 2019. 16 funds tracked by Wall St. Rank hold NBSE as of Q3 2019.

  • Mariner Investment Group reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Mariner Investment Group sold 833 NeuBase Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $57K.
  • Mariner Investment Group first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q4 2017 and held it in 3 quarters.
  • Mariner Investment Group's NeuBase Therapeutics, Inc. Common Stock position peaked at $57K in Q2 2019.
  • 16 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Mariner Investment Group's 13F filing for Q3 2019, filed 12 Nov 2019.